{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:07:16Z","timestamp":1791493636536,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The abscopal effect (AbE) refers to the regression of non-irradiated tumors following localized radiotherapy (RT), suggesting a systemic immune-mediated response. The combination of RT with immunotherapy (IO) has been proposed to enhance the AbE by overcoming RT-induced immunosuppressive mechanisms, but robust evidence, specifically in non-small cell lung cancer (NSCLC), is lacking. This study aimed to determine the prevalence of the AbE and its association with progression-free survival (PFS) and overall survival (OS) in metastatic lung cancer patients receiving RT and IO.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and methods<\/jats:title>\n            <jats:p>We analyzed consecutive metastatic lung cancer patients who received IO at a certified lung cancer center in Germany between 2009 and 2021. Inclusion required RT to at least one lesion and at least one measurable non-irradiated lesion. The AbE was defined as radiological regression of a non-irradiated lesion following RT. PFS and OS were analyzed using Kaplan\u2013Meier estimates and Cox regression models. Factors influencing survival, such as RT site selection and IO duration, were assessed in univariable and multivariable analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 72 patients were included. The AbE was observed in 9.3% (n\u2009=\u20097). While the AbE was significantly associated with prolonged PFS (HR\u2009=\u20090.41, 95% CI: 0.19\u20130.92, <jats:italic>p<\/jats:italic> \u2009=\u20090.03), it did not significantly impact OS (HR\u2009=\u20090.70, 95% CI: 0.30\u20131.64, <jats:italic>p<\/jats:italic> \u2009=\u20090.41). In contrast, RT to the primary tumor (HR\u2009=\u20090.16, <jats:italic>p<\/jats:italic>\u2009=\u20090.004) and longer IO duration (HR\u2009=\u20090.83, <jats:italic>p<\/jats:italic> = 0.001) were strong predictors of improved OS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>While the AbE remains an intriguing phenomenon, its occurrence was rare and not significantly associated with OS. Strategic RT site selection and optimized treatment sequencing were more strongly linked to improved survival outcomes, highlighting the need for refined radioimmunotherapy strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10585-025-10375-w","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T03:34:02Z","timestamp":1758857642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The abscopal effect in metastatic lung cancer: a retrospective analysis of combined radiotherapy and immunotherapy"],"prefix":"10.1007","volume":"42","author":[{"given":"David Alexander","family":"Ziegler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Ambold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus Anton","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif Hendrik","family":"Dr\u00f6ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Ziegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Kieslich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura Anna","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Donath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jona","family":"Bensberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Guhlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Antonia","family":"von Diest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Braulke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"von Hammerstein-Equord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Andreas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achim","family":"Rittmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"El Shafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"issue":"2494","key":"10375_CR1","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1136\/bmj.2.2494.1146","volume":"2","author":"HD McCulloch","year":"1908","unstructured":"McCulloch HD (1908) On the analogy between spontaneous recoveries from cancer and the specific immunity induced by X ray irradiations of the lymphatic glands involved. Br Med J 2(2494):1146\u20131148. https:\/\/doi.org\/10.1136\/bmj.2.2494.1146","journal-title":"Br Med J"},{"issue":"305","key":"10375_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1259\/0007-1285-26-305-234","volume":"26","author":"RH Mole","year":"1953","unstructured":"Mole RH (1953) Whole body irradiation; radiobiology or medicine? Br J Radiol 26(305):234\u2013241. https:\/\/doi.org\/10.1259\/0007-1285-26-305-234","journal-title":"Br J Radiol"},{"issue":"1","key":"10375_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.currproblcancer.2015.10.001","volume":"40","author":"Y Abuodeh","year":"2016","unstructured":"Abuodeh Y, Venkat P, Kim S (2016) Systematic review of case reports on the abscopal effect. Curr Probl Cancer 40(1):25\u201337. https:\/\/doi.org\/10.1016\/j.currproblcancer.2015.10.001","journal-title":"Curr Probl Cancer"},{"issue":"1","key":"10375_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13045-018-0647-8","volume":"11","author":"Y Liu","year":"2018","unstructured":"Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J (2018) Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol 11(1):104. https:\/\/doi.org\/10.1186\/s13045-018-0647-8","journal-title":"J Hematol Oncol"},{"issue":"3","key":"10375_CR5","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L et al (2004) Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 58(3):862\u2013870. https:\/\/doi.org\/10.1016\/j.ijrobp.2003.09.012","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10375_CR6","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. JNCI J Natl Cancer Inst 105(4):256\u2013265. https:\/\/doi.org\/10.1093\/jnci\/djs629","journal-title":"JNCI J Natl Cancer Inst"},{"issue":"7","key":"10375_CR7","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1470-2045(15)00054-6","volume":"16","author":"EB Golden","year":"2015","unstructured":"Golden EB, Chhabra A, Chachoua A, Adams S, Donach M, Fenton-Kerimian M et al (2015) Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. Lancet Oncol 16(7):795\u2013803. https:\/\/doi.org\/10.1016\/S1470-2045(15)00054-6","journal-title":"Lancet Oncol"},{"issue":"10","key":"10375_CR8","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ccell.2021.08.008","volume":"39","author":"Y Lan","year":"2021","unstructured":"Lan Y, Moustafa M, Knoll M, Xu C, Furkel J, Lazorchak A et al (2021) Simultaneous targeting of TGF-\u03b2\/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion. Cancer Cell 39(10):1388\u2013403.e10. https:\/\/doi.org\/10.1016\/j.ccell.2021.08.008","journal-title":"Cancer Cell"},{"issue":"13","key":"10375_CR9","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/s1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16(13):e498-509. https:\/\/doi.org\/10.1016\/s1470-2045(15)00007-8","journal-title":"Lancet Oncol"},{"issue":"17","key":"10375_CR10","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.2217\/imt-2019-0105","volume":"11","author":"E Garelli","year":"2019","unstructured":"Garelli E, Rittmeyer A, Putora PM, Glatzer M, Dressel R, Andreas S (2019) Abscopal effect in lung cancer: three case reports and a concise review. Immunotherapy 11(17):1445\u20131461. https:\/\/doi.org\/10.2217\/imt-2019-0105","journal-title":"Immunotherapy"},{"issue":"9","key":"10375_CR11","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/j.jtho.2017.05.004","volume":"12","author":"T Komatsu","year":"2017","unstructured":"Komatsu T, Nakamura K, Kawase A (2017) Abscopal effect of Nivolumab in a patient with primary lung cancer. J Thorac Oncol 12(9):e143\u2013e144. https:\/\/doi.org\/10.1016\/j.jtho.2017.05.004","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10375_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.4172\/1948-5956.1000443","volume":"9","author":"K Katayama","year":"2017","unstructured":"Katayama K, Tamiya A, Koba T, Fukuda S, Atagi S (2017) An abscopal response to radiation therapy in a patient with metastatic non-small cell lung cancer: a case report. J Cancer Sci Ther 9(2):365\u2013367. https:\/\/doi.org\/10.4172\/1948-5956.1000443","journal-title":"J Cancer Sci Ther"},{"issue":"12","key":"10375_CR13","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-018-0232-2","volume":"24","author":"SC Formenti","year":"2018","unstructured":"Formenti SC, Rudqvist NP, Golden E, Cooper B, Wennerberg E, Lhuillier C et al (2018) Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med 24(12):1845\u20131851. https:\/\/doi.org\/10.1038\/s41591-018-0232-2","journal-title":"Nat Med"},{"key":"10375_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00149-2","author":"NK Altorki","year":"2021","unstructured":"Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Elsevier Ltd et al (2021) Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol. https:\/\/doi.org\/10.1016\/S1470-2045(21)00149-2","journal-title":"Lancet Oncol"},{"key":"10375_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(24)00215-7","author":"ZR Zhao","year":"2024","unstructured":"Zhao ZR, Liu SL, Zhou T, Chen G, Long H, Su XD et al (2024) Stereotactic body radiotherapy with sequential tislelizumab and chemotherapy as neoadjuvant therapy in patients with resectable non-small-cell lung cancer in China (SACTION01): a single-arm, single-centre, phase 2 trial. Lancet Respir Med. https:\/\/doi.org\/10.1016\/S2213-2600(24)00215-7","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10375_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40644-019-0281-x","volume":"20","author":"T Persigehl","year":"2020","unstructured":"Persigehl T, Lennartz S, Schwartz LH (2020) IRECIST: how to do it. Cancer Imaging 20(1):2. https:\/\/doi.org\/10.1186\/s40644-019-0281-x","journal-title":"Cancer Imaging"},{"key":"10375_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00325","volume":"4","author":"RE Vatner","year":"2014","unstructured":"Vatner RE, Cooper BT, Vanpouille-Box C, Demaria S, Formenti SC (2014) Combinations of immunotherapy and radiation in cancer therapy. Front Oncol 4:325. https:\/\/doi.org\/10.3389\/fonc.2014.00325","journal-title":"Front Oncol"},{"issue":"5","key":"10375_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/s2213-2600(20)30391-x","volume":"9","author":"W Theelen","year":"2021","unstructured":"Theelen W, Chen D, Verma V, Hobbs BP, Peulen HMU, Aerts J et al (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9(5):467\u2013475. https:\/\/doi.org\/10.1016\/s2213-2600(20)30391-x","journal-title":"Lancet Respir Med"},{"key":"10375_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001001","author":"J Welsh","year":"2020","unstructured":"Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M et al (2020) Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I\/II trial. J Immunother Cancer. https:\/\/doi.org\/10.1136\/jitc-2020-001001","journal-title":"J Immunother Cancer"},{"issue":"10","key":"10375_CR20","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al (2012) Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 366(10):925\u2013931. https:\/\/doi.org\/10.1056\/NEJMoa1112824","journal-title":"N Engl J Med"},{"issue":"2","key":"10375_CR21","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijrobp.2014.09.018","volume":"91","author":"EB Golden","year":"2015","unstructured":"Golden EB, Formenti SC (2015) Radiation therapy and immunotherapy: growing pains. Int J Radiat Oncol Biol Phys 91(2):252\u2013254. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.09.018","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10375_CR22","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1084\/jem.20052494","volume":"203","author":"EA Reits","year":"2006","unstructured":"Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley E et al (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exper Med 203(5):1259\u20131271. https:\/\/doi.org\/10.1084\/jem.20052494","journal-title":"J Exper Med"},{"issue":"5","key":"10375_CR23","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nrc.2018.6","volume":"18","author":"W Ngwa","year":"2018","unstructured":"Ngwa W, Irabor OC, Schoenfeld JD, Hesser J, Demaria S, Formenti SC (2018) Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 18(5):313\u2013322. https:\/\/doi.org\/10.1038\/nrc.2018.6","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"10375_CR24","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10585-023-10257-z","volume":"41","author":"C Wang","year":"2024","unstructured":"Wang C, Chen L, Fu D, Liu W, Puri A, Kellis M et al (2024) Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade. Clin Exp Metas 41(4):333\u2013349. https:\/\/doi.org\/10.1007\/s10585-023-10257-z","journal-title":"Clin Exp Metas"},{"issue":"11","key":"10375_CR25","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/s43018-022-00456-0","volume":"3","author":"Y Nishiga","year":"2022","unstructured":"Nishiga Y, Drainas AP, Baron M, Bhattacharya D, Barkal AA, Ahrari Y et al (2022) Radiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect. Nat Cancer 3(11):1351\u20131366. https:\/\/doi.org\/10.1038\/s43018-022-00456-0","journal-title":"Nat Cancer"},{"issue":"1","key":"10375_CR26","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12312-022-01153-w","volume":"38","author":"M Trommer","year":"2023","unstructured":"Trommer M, Wegen S, R\u00fchle A, M\u00e4urer M, Wurschi G, Ehret F et al (2023) Abskopale Effekte metastasierter Krebspatient:innen unter Radioimmuntherapie (ARTIC). Forum 38(1):77\u201381. https:\/\/doi.org\/10.1007\/s12312-022-01153-w","journal-title":"Forum"},{"issue":"4","key":"10375_CR27","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/j.ijrobp.2019.03.041","volume":"104","author":"N Sundahl","year":"2019","unstructured":"Sundahl N, Seremet T, Van Dorpe J, Neyns B, Ferdinande L, Meireson A et al (2019) Phase 2 trial of nivolumab combined with stereotactic body radiation therapy in patients with metastatic or locally advanced inoperable melanoma. Int J Radiat Oncol Biol Phys 104(4):828\u2013835. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.03.041","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10","key":"10375_CR28","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1016\/j.ccell.2023.09.007","volume":"41","author":"Y Pan","year":"2023","unstructured":"Pan Y, Zhang J-T, Gao X, Chen Z-Y, Yan B, Tan P-X et al (2023) Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients. Cancer Cell 41(10):1763\u201373.e4. https:\/\/doi.org\/10.1016\/j.ccell.2023.09.007","journal-title":"Cancer Cell"},{"issue":"11","key":"10375_CR29","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1002\/1878-0261.13082","volume":"15","author":"\u00c5K \u00d6jlert","year":"2021","unstructured":"\u00d6jlert \u00c5K, Nebdal D, Snapkov I, Olsen V, Kidman J, Greiff V et al (2021) Dynamic changes in the T cell receptor repertoire during treatment with radiotherapy combined with an immune checkpoint inhibitor. Mol Oncol 15(11):2958\u20132968. https:\/\/doi.org\/10.1002\/1878-0261.13082","journal-title":"Mol Oncol"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10375-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10375-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:16:12Z","timestamp":1760073372000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10375-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":29,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["10375"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10375-w","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the institutional ethical review board of the University Medical Center G\u00f6ttingen, Germany (approval number: 38\/4\/22, approved on May 9, 2022).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"56"}}